ACH-3102 + Sovaldi = 100%

|By:, SA News Editor

Shares of Achillion Pharmaceuticals (ACHN +9.5%) pop on higher volume in response to the company's disclosure that its HCV product candidate, ACH-3102 in combination with Sovaldi (sofosbuvir) cured 12 of 12 patients in a Phase 2 clinical trial. In an interim analysis, 100% of the patients remained HCV RNA undetectable four weeks after completing therapy. Twelve additional patients will now be enrolled in the trial where they will begin six weeks of treatment with once-daily ACH-3102 and sofosbuvir, without ribavirin.